For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Tafamidis and Tafamidis meglumine represents a significant change. These novel therapies protect the transthyretin protein, slowing its destructive build-up and alleviating the severity of the disease . People are now seeing benefit